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ABSTRACT 
Background. One of the most common complications of diabetes mellitus (DM) is diabetic nephropathy (DN).  
Angiotensin- converting enzyme (ACE) gene was the first candidate gene of renin-angiotensin system (RAS) for 
predisposition to DN. 
Objective. Investigation whether the ACE insertion/deletion (I/D) polymorphism is associated with Egyptian type 2 
diabetic patients (T2DM) with nephropathy. In addition, the study investigated the relationship between variants of ACE I/D 
gene polymorphism and serum ACE level and the progression of nephropathy in Egyptian T2DM patients. 
Methods.  A total of 85 T2DM patients (45 with nephropathy and 40 without nephropathy) besides 45 healthy (non-
diabetic) age-matched subjects were recruited in this study for comparison. The (I/D) polymorphism of the ACE gene was 
investigated using PCR and serum ACE levels were determined using ELISA. 
Results. The frequency of ACE DD genotype and D allele was significantly higher in DN patients when compared 
to control healthy subjects and diabetic patients without nephropathy. In addition our results showed a significant 
association between DD genotype of ACE gene and elevated serum ACE level.  
Conclusion. The present study showing a strong association between the D allele and/or DD homozygous of ACE 
gene and diabetic patients developed nephropathy. In addition, individuals with D allele have higher levels of serum ACE 
compared to those having I allele. ACE gene polymorphism and serum ACE level may serve as a susceptibility biomarker 
for nephropathy in type 2 diabetic patients.  
Keywords 
Diabetic nephropathy(DN),Type 2 diabetes mellitus (T2DM), Angiotensin-converting enzyme(ACE) , Gene polymorphism , 
Serum ACE levels. 
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INTRODUCTION 
One of the most common complications of diabetes mellitus (DM) is diabetic nephropathy (DN), a progressive and 
irreversible kidney disease that occurs because of DM 
[1]
. In Egypt the prevalence of nephropathy ranged from 6.7% in 
hospital outpatient clinics to 46.3% in hospital inpatients 
[2]
. Clinically, diabetic nephropathy (DN) is characterized by a 
progressive increase in proteinuria, declining glomerular filtration rate (GFR) and an elevation of arterial blood pressure 
[3; 
4].
 The pathogenesis of diabetic nephropathy is not yet clearly understood, but available data suggest that multiple factors 
contribute to this complication. Poor glycemic control, metabolic abnormalities, hemodynamic alterations, hypertension, 
and genetic factors are the major contributing factors 
[5].
 Studies of familial clustering suggest that genetic predisposition 
plays a role in the development of diabetic nephropathy 
[6]
.  
Among the genes that have been evaluated as possibly conferring susceptibility to advanced nephropathy, the 
angiotensin-converting enzyme (ACE) gene is the most scrutinized. Studies of the ACE (I/D) polymorphism have primarily 
focused on whether the disease is associated with I/D of a 287-bp Alu sequence located in intron 16 
[7]
. Emphasis was 
placed on this particular polymorphism since its D allele has been linked to high levels of serum ACE 
[8]
, a risk factor for 
diabetic nephropathy. Conflicting findings in various populations have been obtained with regard to the role of ACE (I/D) 
polymorphism in diabetic nephropathy 
[9; 10; 11]
 and in type 2 diabetes 
[12; 13]
 that might be attributed to the ethnic 
differences.  
OBJECTIVE 
To our knowledge, no enough data are available concerning the association of ACE gene polymorphism with 
nephropathy in T2DM Egyptian patients. Therefore the current study aimed, to analyze the polymorphisms I/D within ACE 
gene, and evaluate their contribution to susceptibility to nephropathy in T2DM patients. In addition, we studied the 
relationship between variants of ACE I/D gene polymorphism, serum ACE level and progression of nephropathy in type 2 
diabetic patients. 
 PATIENTS AND METHODS: 
1) Study subjects 
This study recruited 85 T2DM patients diagnosed at least 5 years before, the patients consecutively attended the 
diabetes clinic of Internal Medicine Department; Kasr El-Aini Hospital affiliated to Cairo University. Forty five of them (12 
males and 33 females) with nephropathy, while the remaining 40 (9 males and 31 females) without nephropathy. The 
mean age of T2DM patients with nephropathy was 48.47 ± 8.89 years compared to 54.43 ± 8.45 years for the T2DM 
patients without nephropathy. The diagnosis of T2DM was based on the American Diabetes Association criteria, a fasting 
plasma glucose level >126 mg/dL and glycated hemoglobin > 6.5% and/or treated by oral hypoglycemic agents and/or 
insulin to achieve glycemic control. Diabetic nephropathy was defined by persistent albuminuria (albumin-creatinine ratio 
[ACR] > 30 mg/g creatinine) on at least two consecutive occasions over the previous six months. While patients with ACR 
< 30 mg/g creatinine were normoalbuminuric and had no nephropathy. To avoid misclassification diabetic individuals as 
having; abnormal liver function, abnormal thyroid function, advanced renal diseases other than diabetes, cardiovascular 
disease were excluded. 
Beside 45 healthy subjects (17 males and 28 females) with mean age 51.04 ± 7.97 years and without any previous 
history of diabetes or renal disorders were enrolled as control group. The study protocol was approved by the Research 
Ethics Committee, Faculty of Pharmacy- Cairo University (REC-FOPCU). A written informed consent was obtained from 
each participant before testing. 
2) Sampling 
Venous blood was obtained from patients and controls after an overnight fast of 12 h and was divided into three 
portions. One portion of blood (2 ml) was added to EDTA and stored at −20 °C for detection of polymorphism of ACE gene 
and glycated hemoglobin assay. A second portion of 2 ml blood was left for 10 min to clot and then centrifuged at 1000 ×g 
for 5min; the serum was then separated and stored at−20 °C for determination of ACE levels. The last blood portion (1 ml) 
was added to Fluoride and centrifuged at 1000 ×g for 10 min; the plasma was then separated for determination of fasting 
plasma glucose.  
Morning urine samples were collected under aseptic conditions from patients and controls. Urine was centrifuged 
at 500 ×g to get rid of the cells and salts then the supernatant were used for determination of albumin and creatinine. 
Serum ACE level and urinary albumin concentration were assessed using enzyme-linked immunosorbent assay 
(ELISA) kits provided from R&D Systems and DRG-USA, respectively according to the manufacturer's protocol. Fasting 
blood glucose, glycated hemoglobin, urinary total protein and creatinine were measured using commercially available kits 
following the manufacturer's instructions. 
3) Isolation of genomic DNA  
Genomic DNA was isolated from peripheral white blood cells using Qia-amplification extraction kit (Qiagen-USA) 
according to the manufacturer's instructions.  
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4) Genotyping method for I/D polymorphism of ACE gene  
Genotyping was performed on extracted DNA by the polymerase chain reaction (PCR) using  5'-
CTGGAGACCACTCCCATCCTTTCT-3' as sense primer and                                                                  5'-
GATGTCGCCATCACATTCGTCAGAT-3' as antisense primer 
[7]
. The reaction was performed with 5 pmol of each primer 
in combination with Taq PCR Master Mix (Qiagen, Valencia, CA, USA). The PCR cycling was performed with initial 
denaturation at 95°C for 5 min followed by 35 cycles of 94°C for 30 s, 50°C for 30 s, 72°C for 1min, and then by a final 
extension period at 72°C for 7 min (T-Gradient thermal cycler, Biometra, Germany).  
Ten µl of the PCR products were analyzed on 2% agarose gels stained with Red-Safe, the PCR products were either 
490 bps insertion (I allele) or 190 bps deletion (D allele) (Figure 2). The D allele is preferentially amplified in heterozygotes 
giving rise to mistyping of ID as DD in approximately 5% of cases. To avoid such mistyping, samples of DD genotype were 
subject to a second independent PCR with primers that recognize an insertion-specific sequence: 5'-
TGGGACCACAGCGCCCGCCACTAC-3' and 5'-TCGCCAGCCCTCCCATGCCCATAA-3' 
[14]
 with identical PCR condition 
except for annealing temperature at 67°C. Ten µl of the PCR products were analysed on 2% agarose gels stained with 
Red-Safe, the PCR reaction yields a 335 bp DNA product in the presence of the I allele, and no product for homozygous 
DD samples. 
STATISTICAL ANALYSIS 
Data are expressed as means ± standard deviation for quantitative variables, frequency for qualitative variables. 
Quantitative variables were compared using independent Student t-test and One-way ANOVA. LSD test was used for 
multiple post-hoc comparisons. On the other hand, qualitative variables were compared using chi square (χ2) test or 
Fischer's exact test. One-way ANOVA and Chi square test were used to compare the clinical and laboratory 
characteristics of patients divided according to genotypes. The Statistical Package for the Social Sciences software (SPSS 
17.0, Chicago, IL, USA) was used. P< 0.05 was considered significant. 
 RESULTS 
Demographic and biochemical data of the studied groups: 
The demographic and clinical characteristics of type 2 diabetes patients with and without nephropathy and control 
groups are shown in Table 1. There were no statistical significant differences among studied groups regarding sex, insulin 
treatment, hypertension, and urinary creatinine. Regarding age there was significant differences among studied groups 
while, significant was lost between diabetic patients and control group. Diabetic patients with nephropathy had significantly 
higher fasting plasma glucose, glycated hemoglobin, urinary total protein, urinary albumin levels, albumin creatinine ratio, 
serum ACE level, and diabetic duration than the control and diabetic groups. Moreover, the poor diabetic control was 
significant risk factor for progression of nephropathy in diabetic patients. 
 
Table 1: Demographic and clinical characteristics of all subjects. 
 Control 
(n=45) 
T2DM                 without 
nephropathy 
(n=40) 
T2DM                       
with nephropathy 
(n=45) 
P 
Sex 
Male 
Female  
 
17 (37.8%) 
28 (62.2%) 
 
9 (22.5%) 
31 (77.5%) 
 
12 (26.7%) 
33 (73.3%) 
 
 
0.271** 
Age (years) 51.04±7.97 54.43±8.45 48.47±8.89
b
 0.006* 
Diabetes duration (years) --- 8±4 10.98±4.8
b
 <0.001* 
Treatment 
Insulin 
Non-Insulin  
 
--- 
--- 
 
 
16 (40%) 
24 (60%) 
 
26 (57.8%) 
19 (42.2%) 
 
 
0.078*** 
Pressure 
Normal 
High 
 
--- 
--- 
 
27 (67.5%) 
13 (32.5%) 
 
23 (51.1%) 
22 (48.9%) 
 
 
0.095*** 
Fasting plasma glucose ( mg/dl) 86.3±7.99 246.3±76.1
a
 289.3±98.35
ab
 <0.001* 
Glycated haemoglobin (%) 5.4±0.3 8.786±1.45
a
 9.92±1.95
ab
 <0.001* 
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Diabetic Control  
Good 
Fair 
Poor 
 
--- 
--- 
--- 
 
26 (65%) 
10 (25%) 
4 (10%) 
 
18 (40%) 
5 (11.1%) 
22 (48.9%) 
 
 
 
<0.001** 
Urinary total protein (mg/L) 34.6±9.3 97.2±50.3
a
 449.8±130.3
ab
 <0.001* 
Urinary-albumin (mg/L) 6.9±1.9 13.97±9.96 89.6±66.4
ab
 <0.001* 
Urinary creatinine (g/L) 1.05±0.27 1.14±0.379 0.98±0.437
b
 1.36* 
Albumin creatinine ratio (mg/g)  6.95±2.5 12.95±9.03 104.5±93.3
ab
 <0.001* 
Serum ACE level (ng/ml) 92.8±34.4 115.23±44.58
a
 149.5±39.78
ab
 <0.001* 
T2DM = Type 2 diabetes mellitus, ACE = Angiotensin converting enzyme. 
Data are expressed as mean ± SD for quantitative variable or number (%) for qualitative one 
* 
One way ANOVA test  
**
 Chi square test
   ***
 Fisher exact test   
a
 Significantly different from control,  
b
 Significantly different from T2DM without nephropathy. 
Bold values indicate significant difference  P value < 0.05 was considered significant. 
 
Serum ACE level 
Table 2 shows the frequency of samples detected by ELISA for ACE Level. While, Table 3 shows the sensitivity 
(Sn), specificity (Sp), positive predicative value (PPV), negative predictive value (NPV), accuracy, positive likelihood ratio, 
(PLR), negative likelihood ratio (NLR) and Diagnostic Index calculated for ACE level. At ACE value of 117.5 (ng/ml), the 
sensitivity and NPV values were 82.2% & 77.78% respectively, but the specificity (70%) and PPV (75.51%) decreased. In 
ROC analysis, the area under the receiver characteristic curve for ACE value (0.761+.055) indicating a greater ability of 
ACE Values for distinguishing diabetic nephropathy from diabetic without nephropathy  group (Figure 1). For diabetic 
nephropathy, positive and negative likelihood ratios (PLR, NLR) for serum ACE, showed small changes but there were no 
significant changes observed in the PLR and NLR with diabetic without nephropathy. 
 
Figure 1: Receiver operating characteristic curve for ACE level (the area under the receiver characteristic curve 
for ACE value (0.761+0.055), 95% CI: 65.4% - 86.8%) 
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Table 2: Frequency of Samples detected by ELISA for ACE Level 
Parameter DM 
(n = 40  ) 
DN 
(n=45 ) 
P value 
(ACE level) 
Negative(n=36) 
28 8 
0.0001 
(ACE level) 
Positive(n=49 
12 37 
 
 
                                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3. Genotype distribution and allele 
frequencies of I/D polymorphism for the 
ACE gene  
ACE I/D polymorphism was assessed and is 
represented in Figure 2, with the 490 bp band indicating II 
genotype, 490 and 190 bp indicating ID genotype, and 190 
bp indicating DD genotype. The distribution of ACE I/D 
genotype and its allele frequency for the studied groups are 
summarized in Table 4.  
Figure 2: Detection of ACE (I/D) polymorphism by 
electrophoresis in a 2% agarose gel stained with Red-Safe. 
The PCR products were visualized under UV light. 
M: Molecular DNA marker (100-1000 bp) 
Lanes 1, 2: II homozygous at 490 bp 
Lanes 3,4: ID heterozygous at 490, 190 bp 
Lanes 5, 6: DD homozygous at 190 bp 
The results showed significantly higher DD genotype 
distribution and D allele frequency in type 2 diabetes 
patients who progressed nephropathy than in control (P = 
0.035, P = 0.008, respectively) and type 2 diabetes without 
nephropathy (P < 0.001, P < 0.001, respectively). When the 
pure mutant DD genotype was pooled with ID and II, we 
found the DD genotype to be higher in the nephropathy 
group than in the control and diabetic groups.  
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Table 4: Genotype distribution and allele frequencies of the ACE (I/D), gene polymorphism in the studied groups 
 Control 
(n=45) 
T2DM                 
without 
nephropathy 
(n=40) 
T2DM                       
with 
nephropathy 
(n=45) 
P* P** 
ACE Genotype      
II
a
 21 (46.71%) 10 (25%) 7 (15.6%)   
ID   18 (40%)   20 (50%) 13 (28.9%) 0.17 0.903 
DD
b
   6 (13.3%)   10 (25%) 25 (55.6%) <0.001 0.035 
DD+ID
a
 24 (53.3%) 30 (75%) 38 (84.4%)   0.001 0.277 
II+ID
b
 39 (86.7%) 30 (75%) 20 (44.4%) 
 
<0.001 0.004 
Allele      
I  60 (66.7%)   40 (50%)   27 (30%)   
D   30 (33.3%)   40 (50%)   63 (70%) <0.001 0.008 
Data are number (%), variables were compared using chi square (χ2) test or Fischer's exact test. 
a 
II vs ID+DD    
b
 DD vs II+ID 
*P values for comparison between T2DM with nephropathy & controls,  
**P values for comparison between T2DM with nephropathy & T2DM without nephropathy. 
Bold values indicate significant difference  P value < 0.05 was considered significant. 
 
3.4. Characteristics of diabetic nephropathy patients with different ACE genotypes 
Characteristics of diabetic nephropathy patients with different ACE genotypes are shown in Table 5. The 
comparison revealed no significant differences in fasting plasma glucose, urinary total protein, urinary albumin levels, 
albumin creatinine ratio, diabetic duration, and insulin treatment among diabetic nephropathy patients with different ACE 
genotypes. Whereas, there was a significant association between elevated glycated hemoglobin, serum ACE level, poor 
diabetic control, and ACE DD pure mutant genotype. 
 
Table 5: Characteristics of T2DM patients with and without nephropathy among different I/D genotypes on ACE 
gene 
    ACE I/D (without nephropathy) 
                           
ACE I/D (with nephropathy) 
DD  
(n= 10) 
ID+II  
(n=30) 
P* value DD 
 (n= 25) 
ID+II  
(n=20) 
P** 
value 
Sex (M/F) 3/7 6/24 0.665 10/15 2/18 0.024 
Age (years) 54.7±9.093 54.33±8.39 0.907 48.12±10.75 48.9±6.05 0.774 
Diabetes duration 
(years) 
8.9±4.67 7.7±3.9 0.428 
11.2±5.16 10.7±4.65 0.737 
Treatment 
           Insulin 
           Non-Insulin 
 
3 
7 
 
13 
17 
0.771 
 
13 
12 
 
13 
7 
 
0.38 
Fasting plasma 
glucose ( mg/dl) 
229.5±82.9 251.9±74.3 0.427 
287.8±101.4 291.25±96.99 0.909 
Glycated haemoglobin 
(%) 
9.12±2 8.675±1.2 0.41 
10.46±1.9 9.2±1.8 0.034 
    ISSN 2321-807X 
2029 | P a g e                                                            M a y  1 9 ,  2 0 1 4  
Diabetic Control  
Good 
Fair 
                 Poor 
 
7 
1 
2 
 
19 
9 
2 
 
0.275 
 
 
6 
2 
17 
 
12 
3 
5 
 
0.016 
Urinary total protein 
(mg/L) 
92.95±43.3 98.65±52.99 0.761 
459.4±139.5 437.85±120.3 0.587 
Urinary-albumin (mg/L) 9.81±7.7 15.36±10.3 0.129 91.7±77.99 86.97±50.09 0.815 
Urinary creatinine (g/L) 1.24±0.48 1.1±0.339 0.353 0.91±0.39 1.066±.048 0.246 
Albumin creatinine 
ratio (mg/g) 
9.2±7.3 14.2±9.3 0.129 
118.5±119.5 87±39.5 0.266 
Serum ACE level 
(ng/ml) 
155.5±63.6 101.8±25.8 <0.001 
166.5±31.99 128.3±38.99 0.001 
Data are expressed as mean ± SD for quantitative variable or number for qualitative one 
One-way ANOVA and Chi square test were used to compare the clinical and laboratory characteristics of patients divided according to 
genotypes. 
*P values for comparison within T2DM without nephropathy group,  
**P values for comparison within T2DM with nephropathy group. 
Bold values indicate significant difference   
P<0.05 was considered significant. 
4. Discussion   
Diabetic nephropathy is the outcome of various pathophysiological processes, such as hydrodynamic alterations, 
metabolic abnormalities, various growth factors, and genetic factors. Genetic predisposition plays a role in the 
development of diabetic nephropathy, which clusters within families in both type 1 and type 2 diabetes. 
Many of the previous studies of the association between ACE polymorphism and diabetic nephropathy yielded 
conflicting results. Several factors, including variations in ethnic background of the cases and controls, the possible criteria 
of inclusion and exclusion, and lack of statistical power due to small sample sizes, may be responsible for the 
contradictory results. 
The ACE gene is one of the important genes in RAS pathway. To examine the effect of the ACE gene I/D 
polymorphism to develop nephropathy in T2DM patients, T2DM patients with nephropathy were compared with healthy 
non-diabetic control subjects and also compared with T2DM patients without nephropathy. The outcome was as follows: 
the DD genotype was significantly higher in DN than healthy non-diabetic control subjects and T2DM patients without 
nephropathy. Moreover, the frequency of the D allele was also higher in DN compared to healthy non-diabetic subjects 
and T2DM patients without nephropathy. This finding raises the suspicion that the D allele or DD homozygous is 
accompanying with the progression of nephropathy in type 2 diabetic patients. These observations are in agreement with 
other previous studies, a meta-analysis of data from 18 studies, which included 14,108 diabetic nephropathy patients and 
12,472 controls, reported significant association between the ACE I/D polymorphism and the risk of nephropathy for all 
genetic models 
[15]
. A strong association between the ACE DD genotype and/or the D allele and the risk for nephropathy in 
type 2 diabetes was found in Malaysian, 
[16]
; British Caucasian, 
[17]
; Bahraini, 
[18]
 and also in Japan 
[19]
, USA 
[20]
, and Iran 
[21]
. On the other hand, data from other studies (Chinese, 
[22]
; German, 
[23]
; Danish, 
[24]
; Turkish, 
[25]; 
Iranian, 
[26]
; Tunisian, 
[11]
) failed to confirm an association of the ACE I/D gene polymorphism with diabetic nephropathy.  
The data from India also show contradictory results. Viswanathan et al. 
[27]
, Naresh et al. 
[28]
 and Bhavani et al. 
[29]
 
show a positive association with the D allele (ID and DD genotypes) of the ACE polymorphism and diabetic nephropathy in 
their South Indian populations, whereas Bhaskar et al. 
[30]
 in South Indian and Prasad et al. 
[31]
 and Kumar et al. 
[32]
 in 
North Indian populations found no relation between ACE polymorphism and development of nephropathy in type 2 diabetic 
patients. These conflicting results may be due to several factors, mainly ethnicity. 
A meta-analysis of 47 studies published from 1994 to 2004, demonstrated that the II genotype has reduced the risk 
of DN compared to the D-allele carriers 
[33]
. In fact, the deletion polymorphism is associated with elevated serum and 
cellular ACE levels 
[34; 35].
 The elevated ACE expression increases the plasma angiotensin II level, and promotes podocyte 
injury which leads to progressive kidney diseases as well as DN 
[36].
 In the current study, there was a significant 
association between DD genotype of ACE gene and elevated serum ACE level.  
In addition, the mutant DD genotype of ACE I/D polymorphism exhibited significant association with elevated 
glycated hemoglobin level and poor diabetic control.  
Our study shows that other factors such as glycated hemoglobin, poor diabetic control, and serum ACE level are 
also responsible for development of diabetic nephropathy. 
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IN CONCLUSION, 
 The present study supports the data that show the ACE I/D polymorphism may be used as a genetic risk factor for 
diabetic nephropathy in type 2 diabetes mellitus cases. As this study is limited with less number of cases and controls, the 
genotypic and allelic differences that observed may not represent a true association. Hence, additional studies considering 
gene-gene and gene-environment interactions should be investigated to estimate the overall risk of the ACE gene in the 
pathogenesis of diabetic nephropathy. 
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